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Abstract 
 
Multiple Sclerosis (MS) is a chronic neurological disease characterized by demyelination 
associated with infiltrating white blood cells in the central nervous system (CNS). Nitric 
oxide synthases (NOS) are a family of enzymes that control the production of nitric oxide. It 
is possible that neuronal NOS could be involved in MS pathophysiology and hence the nNOS 
gene is a potential candidate for involvement in disease susceptibility. The aim of this study 
was to determine whether allelic variation at the nNOS gene locus is associated with MS in an 
Australian cohort. DNA samples obtained from a Caucasian Australian population affected 
with MS and an unaffected control population, matched for gender, age and ethnicity, were 
genotyped for a microsatellite polymorphism in the promoter region of the nNOS gene. Allele 
frequencies were compared using chi-squared based statistical analyses with significance 
tested by Monte Carlo simulation. Allelic analysis of MS cases and controls produced a chi-
squared value of 5.63 with simulated P=0.96 (OR(max)=1.41, 95% CI: 0.926–2.15). Similarly, 
a Mann–Whitney U analysis gave a non-significant P-value of 0.377 for allele distribution. 
No differences in allele frequencies were observed for gender or clinical course subtype 
(P>0.05). Statistical analysis indicated that there is no association of this nNOS variant and 
MS and hence the gene does not appear to play a genetically significant role in disease 
susceptibility.  
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1. Introduction 
Multiple Sclerosis (MS) is a chronic disease affecting the central nervous system (CNS). The 
disorder is characterized by demyelination associated with an infiltration of mononuclear 
white blood cells within the CNS. The demyelination leads to an impairment of the action 
potential conduction along neurons. MS results in neurological impairment characterized by 
limb weakness, sensory loss, visual alterations, bladder dysfunction and many other 
complications [1]. 
 
The aetiology of MS remains unknown, but is thought to be due to polygenetic and 
environmental factors [2]. A significant genetic component is supported by disease 
concordance of monozygotic twins and dizygotic twins, which shows a remarkable incidence 
of 25% and 4%, respectively, compared to a 0.1% incidence in the overall population [3]. A 
recent full genome scan has implicated several chromosomal regions, with the strongest 
evidence for a susceptibility region at the major histocompatibility (MHC) locus on 
chromosome 6p21 [4]. Linkage studies also indicate the presence of an MS locus on 
chromosome 12q24.2 [5]. This genomic region is known to harbour the neuronal nitric oxide 
synthase gene (nNOS) [6]. 
 
Nitric oxide (NO) production arising from nNOS has been involved in the pathophysiology of 
several disorders of the brain [7, 8 and 9]. NO has been shown to be toxic to oligodendrocytes 
and to induce axonal degeneration [10 and 11]. Also, nNOS can be induced in response to 
nerve injury [12]. An increased concentration of NO degradation product, nitrate, is found in 
cerebrospinal fluid (CSF) of MS patients [13]. Also, within active MS lesions intense 
nitrotyrosine residues are found as indicated by the presence of the oxidised agent, 
peroxynitrite [14]. Furthermore, in an MS-like disease model, Experimental Allergic 
Encephalomyeletis (EAE) mice, NO scavengers have been shown to decrease the severity of 
the EAE condition [13]. Nitric oxide is also known to be a modulator of neuronal function 
affecting the release of neurotransmitters and playing a role in long-term potentiation, as well 
as long-term depression [15]. Interestingly, A 5′-flanking region immediately upstream of the 
starting region of nNOS gene has been found to be associated with Parkinson's disease [16]. 
Although the nNOS gene has not been found to be associated with MS in multiplex Swedish 
families [17 and 18], we present a study investigating whether an nNOS gene polymorphism 
is associated with MS in an Australian population. 
2. Materials and methods 
2.1. Subjects 
The study protocol was approved by Griffith University's ethics committee for 
experimentation on humans. The association population consisted of 104 MS-affected 
individuals and 104 controls, matched for ethnicity (Caucasian), sex and age (±5 years). The 
MS population was obtained from patients from the Multiple Sclerosis Clinic at the Royal 
Brisbane Hospital, all from the South East Queensland region. The MS population consisted 
of 75% females and 25% males and were subdivided into three clinical courses: Relapsing–
Remitting MS (RR-MS), Secondary Progressive MS (SP-MS), Primary Progressive MS (PP-
MS) with frequencies of 40%, 36%, 24%, respectively. The control group was also obtained 
from the South East Queensland region through the Genomics Research Centre, Southport, 
with each control, age (±5 years), sex, and ethnicity matched to the affected population. All 
individuals gave informed consent before participating in the research. Genomic DNA was 
extracted from peripheral blood using a standard salting-out protocol. 
2.2. Genotyping 
Primers and PCR conditions for the dinucleotide repeat of nNOS have been described by Xu 
and Hillert [18]. Primers were 5′-CCT GCG TGG CTA CTA CTA TC-3′ and 5′-AGA CGT 
CGC AAC CCT CAT TA-3′. Primers were purchased from GeneWorks. Optimal PCR 
conditions consisted of 95 °C for 1 min, 55 °C for 40 s and 72 °C for 1 min with 30 cycles 
using a PCR thermocycler machine (Gene Amp PCR System 9700; Applied Biosystems). The 
fragment containing the dinucleotide repeat was amplified and run on an ethidium bromide 
stained 2% agarose gel. Capillary electrophoresis was performed on an ABI 310 Genetic 
Analyser. Results were analyzed using GENOTYPER® software (version 2.1; PE 
Biosystems). The accuracy and reproducibility of automated sizing of the fragments were 
confirmed by randomly chosen repeated analyses of identical samples. 
2.3. Statistical analyses 
The CLUMP program was used to derive a chi-square ( 2) value and P-values simulated 
using the Monte Carlo approach. From this analysis, it is possible to determine whether there 
is a significant difference between allele frequencies in cases and controls. Monte Carlo 
simulation, as opposed to the standard chi-squared distribution, was used to estimate 
significance as the number of alleles is large and the corresponding contingency table sparse 
(many cells <5 expected). The CLUMP program generates two statistics of importance, the 
normal chi-squared (T1) which is derived using the raw 2-by-m table or the chi-squared for 
the "clumped" 2×2 table (T4), in which columns of the original table are clumped to 
maximise the chi-squared value. The CLUMP program was run over 5000 simulations to 
estimate a P value for this analysis. 
 
Additionally, an analysis using the Wilcoxon–Mann–Whitney test was performed. This 
method uses a ranking approach to determine whether the allele distributions of the groups 
are statistically different. Significance for this test was also estimated using the Monte Carlo 
simulations as the standard assumptions for performing a Wilcoxon–Mann–Whitney test were 
also violated due to the large numbers of alleles. For both analyses, an =0.05 significance 
level was used. Power estimates suggested that if an allele of frequency 0.15 were to confer a 
modest twofold increase in relative risk of multiple sclerosis, and assuming near complete 
linkage disequilibrium between this allele and the direct MS-influencing allele, the case and 
control groups used in this study were of sufficient size to have ≥80% power to detect an 
association at the 0.05 level [19]. 
3. Results 
To determine whether a dinucleotide polymorphism of nNOS (Table 1) was associated with 
susceptibility to MS, allelic data from 104 MS cases and 104 controls was analyzed. In this 
Australian population, 13 alleles of this polymorphism were identified with sizes ranging 
from 182 to 210 bp. Controls displayed a heterozygosity value of 0.86, which is consistent 
with previously published heterozygosity values for this polymorphism. The allele 
distribution (Table 2) showed that allele 10 was the most prevalent allele in both groups 
(~33%). We compared the NOS1 variant data of our MS control group with the control group 
of a similar MS case control study in Sweden [17]. This comparison indicated that the allele 
frequency distributions were very similar despite the different ethnic backgrounds of the 
samples ( 2=10.2, P=0.54).  
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2 analysis revealed no significant difference between MS cases and the control group. (CLUMP T1 
2=5.628, P=0.962, T4 2=2.573, P=0.9402). 
Allele frequency distributions of MS cases and controls were compared using the 2 test to 
determine whether an association exists between the polymorphism and the disease. This 
analysis, using Monte Carlo simulations implemented in the CLUMP program, produced a T1 
2 value of 5.628 with a simulated P value of 0.962 and a T4 2 of 2.573 with a simulated P 
value of 0.9402. The T4 statistic was achieved by clumping alleles 1, 2, 3, 8 and 13 together, 
and comparing this to the clumped remaining alleles. This analysis indicates that the nNOS 
variant does not confer an altered effect on MS (OR(max)=1.41, 95% CI: 0.926–2.15). Rank 
analysis also indicated that allelic distributions were not significantly different between test 
groups (Z=−0.868, P=0.377). Stratified analyses testing for a gender-specific relationship 
between MS and nNOS and comparisons of a specific clinical course group were also 
negative for association (P>0.05). 
4. Discussion 
MS aetiology remains unknown but evidence from several studies suggests a genetic 
component may be influencing disease susceptibility [20 and 21]. NOS isoenzymes are 
encoded by three genes: NOS1 (neuronal NOS) on chromosome 12 (12q 24.2), NOS2 
(macrophage inducible NOS) on 17 cen-q12 and NOS 3 (endothelial NOS) on 7 q35–36. 
NOS1 and NOS 3 are constitutive enzymes and calcium-dependent, whereas NOS2 is an 
inducible protein and calcium-independent. NO is produced by neurons and by infiltrating 
macrophages within MS lesions. In the present work, we studied a dinucleotide repeat 
polymorphism in the nNOS gene, in patients with different subgroups of multiple sclerosis 
and compared it with the genotypes of healthy controls that had no history of MS. 
This study indicated no association of the tested nNOS polymorphism in an Australian MS 
population. Our findings support those obtained for an ethnically different Swedish 
population [17 and 18]. Despite these findings, it is still possible that NOS is implicated in 
MS susceptibility. The gene nNOS has been shown to be induced in response to nerve injury 
and in the case of MS, multiple studies show axonal damage in this pathology [22, 23 and 
24]. It has been shown that NO production within MS plaques is capable of producing 
neoantigens on proteins due to direct S-nitrosylation of cysteine residues. The emergence of 
new epitopes can lead to the presence of antibodies which have been found in patients with 
different clinical forms of Multiple Sclerosis [25]. Hence, although our study does not support 
a role for the tested neuronal NOS genetic variant in this disorder, NO may play a role in MS 
pathology.  
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